Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy
- PMID: 19268439
- DOI: 10.1016/j.canlet.2009.01.034
Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy
Abstract
Lack of sensitive and specific biomarkers is a major reason for the high rate of hepatocellular carcinoma (HCC) related mortality. The aim of this study was to use surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy (SELDI-TOF-MS) technology to identify potential protein patterns specific for HCC. Eighty-one patients with hepatitis B-related HCC and 80 healthy controls were randomly divided into a training set (48 HCC, 47 controls) and a testing set (33 HCC, 33 controls). Serum proteomic profiles were measured using SELDI-TOF-MS. A classification tree was established by Biomarker Pattern Software. Candidate biomarkers were separated by HPLC and identified by MALDI-MS/MS and database searching. Forty-eight HCC cases, 54 liver cirrhosis cases and 42 healthy people were clinically validated using candidate biomarkers by SELDI-Immunoassay. Two up-regulated protein peaks were automatically chosen as a classification tree in the training set. These biomarkers were identified as thrombin light chain and growth related oncogene-alpha (GRO-alpha). The sensitivity and specificity of this classification tree were 89.6%. The multivariate model using the two biomarkers and AFP resulted in a sensitivity of 91.7% and specificity of 92.7%, which was significantly better than that of alpha-fetoprotein alone. We conclude that thrombin light chain and GRO-alpha are potential biomarkers of HCC.
Similar articles
-
Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.Clin Cancer Res. 2008 Jan 15;14(2):470-7. doi: 10.1158/1078-0432.CCR-07-0586. Clin Cancer Res. 2008. PMID: 18223221
-
Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.J Gastroenterol Hepatol. 2009 Jan;24(1):55-62. doi: 10.1111/j.1440-1746.2008.05580.x. Epub 2008 Sep 24. J Gastroenterol Hepatol. 2009. PMID: 18823443
-
SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.J Exp Clin Cancer Res. 2007 Dec;26(4):505-8. J Exp Clin Cancer Res. 2007. PMID: 18365545
-
Proteomics in the diagnosis of hepatocellular carcinoma: focus on high risk hepatitis B and C patients.Anticancer Res. 2006 Sep-Oct;26(5A):3293-300. Anticancer Res. 2006. PMID: 17094443 Review.
-
Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways.Liver Int. 2007 Oct;27(8):1021-38. doi: 10.1111/j.1478-3231.2007.01533.x. Liver Int. 2007. PMID: 17845530 Review.
Cited by
-
Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.Liver Int. 2014 Oct;34(9):1428-44. doi: 10.1111/liv.12541. Epub 2014 Apr 28. Liver Int. 2014. PMID: 24661807 Free PMC article.
-
Severe childhood malaria syndromes defined by plasma proteome profiles.PLoS One. 2012;7(12):e49778. doi: 10.1371/journal.pone.0049778. Epub 2012 Dec 4. PLoS One. 2012. PMID: 23226502 Free PMC article.
-
The Clinical Significance and Role of CXCL1 Chemokine in Gastrointestinal Cancers.Cells. 2023 May 17;12(10):1406. doi: 10.3390/cells12101406. Cells. 2023. PMID: 37408240 Free PMC article. Review.
-
CD147 Promotes CXCL1 Expression and Modulates Liver Fibrogenesis.Int J Mol Sci. 2018 Apr 10;19(4):1145. doi: 10.3390/ijms19041145. Int J Mol Sci. 2018. PMID: 29642635 Free PMC article.
-
Disease monitoring of hepatocellular carcinoma through metabolomics.World J Hepatol. 2017 Jan 8;9(1):1-17. doi: 10.4254/wjh.v9.i1.1. World J Hepatol. 2017. PMID: 28105254 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical